Our History and Future

Ourgroup Landingpage C1 Historyandfuture

Our History

Since 1926, the Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Paris, France, Guerbet is a publicly traded company on Euronext Paris (segment B – mid caps) and a leader in medical imaging worldwide. Guerbet’s legacy actually begin in 1901 when Marcel Guerbet discovered the first iodinated organic contrast medium, known today as Lipiodol^{^®}(Ethiodized Oil) Injection. Our teams contribute to progress made in the diagnosis of major disease areas (cancer, cardiovascular, inflammatory and neurodegenerative diseases). Our novel and effective imaging solutions help to improve patient management throughout the world.

Marcel Guerbet discovers Lipiodol^{^®} (ethiodized oil) Injection. André Guerbet founded the Laboratoire André Guerbet et Cie

Michel Guerbet succeeds his father as head of the company (100 employees and 5 million francs in sales)

Guerbet (GBT) listed on the Paris Stock Exchange

Dotarem^{^®} (gadoterate meglumine) Injection launched in the USA

Acquisition of Mallinckrodt's contrast media and delivery system (CMDS) including Liebel-Flarsheim™ Company power injectors and urology systems: Guerbet doubles its size and becomes a world leader in medical imaging

Acquisition of microcatheters from Accurate Medical Therapeutics: Guerbet accelerates in interventional imaging

Launch of new Digital Solutions portfolio

David Hale becomes CEO

Jared Houk appointed as Vice President of North America

Our Mission: Performance, Quality and Sustainable Development

Guerbet’s mission is to provide healthcare professionals with contrast media, medical devices and innovative solutions that are vital for diagnostic and interventional imaging, to help providers improve patient prognosis and quality of life. Driven by our passion for our work, we strive to combine performance, quality and sustainable development in our daily work.

Our Vision: Expanding Digital Technologies and Artificial Intelligence

Guerbet has launched a strategic initiative to develop a new business based on digital technologies and artificial intelligence in two phases; the first, for predictive AI products for radiologists to improve workflow and efficiency; and second, to develop diagnostic assistance tools facilitating capabilities such as obtaining a tumor tissue characterization through imaging to better guide treatments or even eventually replace a biopsy.

Liebel-Flarsheim™ Company LLC, a wholly-owned subsidiary of Guerbet Group

Founded in 1917, Liebel-Flarsheim™ Company LLC (L-F) became an early innovator in electronics for healthcare. In 1921, they introduced the first imaging table designed specifically for urological examinations.

In 2015, Guerbet acquired Mallinckrodt's contrast media and delivery system (CMDS) including Liebel-Flarsheim™ Company power injectors and urology systems with primary manufacturing facilities in Cincinnati, Ohio and Raleigh, North Carolina. The Hydra Vision™ Digital Imaging System, which is used in urological, gastroenterological, and gynecological treatment, planning and diagnostic exams, is produced in Cincinnati along with Guerbet’s line of power contrast injectors for MR, CT and cardiac cath lab. The Raleigh, North Carolina location produces contrast media for diagnostic imaging tests in CT, MR and cardiac cath lab.